CN117026253A - 不对称脱氢偶联合成手性四氢异喹啉类化合物的方法 - Google Patents
不对称脱氢偶联合成手性四氢异喹啉类化合物的方法 Download PDFInfo
- Publication number
- CN117026253A CN117026253A CN202311057957.5A CN202311057957A CN117026253A CN 117026253 A CN117026253 A CN 117026253A CN 202311057957 A CN202311057957 A CN 202311057957A CN 117026253 A CN117026253 A CN 117026253A
- Authority
- CN
- China
- Prior art keywords
- asymmetric
- chiral
- synthesizing
- coupling according
- tetrahydroisoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 15
- 238000010168 coupling process Methods 0.000 title claims abstract description 14
- 238000005859 coupling reaction Methods 0.000 title claims abstract description 14
- UWYZHKAOTLEWKK-UHFFFAOYSA-N tetrahydro-isoquinoline Natural products C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 title claims abstract description 14
- -1 tetrahydroisoquinoline compound Chemical class 0.000 title claims abstract description 12
- 230000008878 coupling Effects 0.000 title claims abstract description 7
- 238000006356 dehydrogenation reaction Methods 0.000 title claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 31
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 claims abstract description 18
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000002808 molecular sieve Substances 0.000 claims abstract description 11
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims abstract description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 9
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003054 catalyst Substances 0.000 claims abstract description 6
- 238000005868 electrolysis reaction Methods 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 229940125904 compound 1 Drugs 0.000 claims abstract description 3
- 229940126214 compound 3 Drugs 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 13
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 claims description 2
- SZAKAAGHPLUEPM-UHFFFAOYSA-N 9-$l^{1}-oxidanyl-9-azabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1N2[O] SZAKAAGHPLUEPM-UHFFFAOYSA-N 0.000 claims description 2
- LJXUEIZPEKVEBH-UHFFFAOYSA-N B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] Chemical group B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.B([O-])([O-])F.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] LJXUEIZPEKVEBH-UHFFFAOYSA-N 0.000 claims description 2
- 239000010405 anode material Substances 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 239000010406 cathode material Substances 0.000 claims description 2
- 229910021397 glassy carbon Inorganic materials 0.000 claims description 2
- 229910002804 graphite Inorganic materials 0.000 claims description 2
- 239000010439 graphite Substances 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229910001501 sodium hexafluoroborate Inorganic materials 0.000 claims description 2
- 238000011914 asymmetric synthesis Methods 0.000 abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 230000007613 environmental effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000007547 defect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- ULTQUFCPWDEOND-FOLHBFKUSA-N β-isocupreidine Chemical compound C1=C(O)C=C2C([C@H]3C4CC5CCN4C[C@@]5(O3)CC)=CC=NC2=C1 ULTQUFCPWDEOND-FOLHBFKUSA-N 0.000 description 3
- LVVKXRQZSRUVPY-HNNXBMFYSA-N (S)-coclaurine Chemical compound C([C@@H]1NCCC=2C=C(C(=CC=21)O)OC)C1=CC=C(O)C=C1 LVVKXRQZSRUVPY-HNNXBMFYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 2
- 229960000977 trabectedin Drugs 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- YRYCIFUZSUMAAY-UHFFFAOYSA-N (RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline Chemical class N1CCC2=CC=CC=C2C1CC1=CC=CC=C1 YRYCIFUZSUMAAY-UHFFFAOYSA-N 0.000 description 1
- DEUJSGDXBNTQMY-UHFFFAOYSA-N 1,2,2-trifluoroethanol Chemical compound OC(F)C(F)F DEUJSGDXBNTQMY-UHFFFAOYSA-N 0.000 description 1
- GNVXOIRECQQWBJ-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3,4-dihydro-1h-isoquinoline Chemical compound C1=CC(OC)=CC=C1N1CC2=CC=CC=C2CC1 GNVXOIRECQQWBJ-UHFFFAOYSA-N 0.000 description 1
- ONQBUHWENXKHHP-UHFFFAOYSA-N 2-phenyl-3,4-dihydro-1h-isoquinoline Chemical compound C1CC2=CC=CC=C2CN1C1=CC=CC=C1 ONQBUHWENXKHHP-UHFFFAOYSA-N 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000251555 Tunicata Species 0.000 description 1
- HFIVLLBFACNAFN-UHFFFAOYSA-N [1-amino-2-[2-(4-methoxyphenyl)ethylamino]ethyl]phosphonic acid Chemical compound COc1ccc(CCNCC(N)P(O)(O)=O)cc1 HFIVLLBFACNAFN-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
- C25B3/00—Electrolytic production of organic compounds
- C25B3/01—Products
- C25B3/09—Nitrogen containing compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,属于有机化学中不对称合成领域。以N‑芳基四氢异喹啉类化合物1和丙烯醛2为原料,在β‑6'‑羟基异辛可宁催化剂存在下,加入六氟磷酸钠、2,2,6,6‑四甲基哌啶氧化物、
Description
技术领域
本发明具体涉及不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,属于有机化学中不对称合成领域。
背景技术
C1-手性四氢异喹啉类化合物具有重要生理活性,Schofield等从加勒比红树海鞘中分离得到四氢异喹啉结构海鞘素Ecteinascidin 743被发现对人体内的肿瘤细胞具有高效杀伤作用,有较强抗肿瘤活性。Kashiwada等从莲花叶片中分离得到苄基四氢异喹啉类生物碱(+)-1-(R)-乌药碱Coclaurine能够抑制人T淋巴细胞H9中HIV病毒复制,其他手性四氢异喹啉类化合物在治疗高血压、止咳、治疗真菌感染、抗凝血等方面发挥着重要的作用。
目前此类化合物的合成主要有两种途径:第一种途径为传统多步合成法,该法存在反应步骤长,操作繁琐,收率较低等缺点;第二种途径为不对称催化的方法,即利用手性催化剂参与不对称反应,该类方法存在需使用氧化剂、金属催化剂或催化效率低等缺点。
因此,开发更加简单高效和绿色不对称合成方法构建手性四氢异喹啉类化合物仍是非常必要的。
发明内容
为了克服上述缺陷,本发明公开了不对称脱氢偶联合成手性四氢异喹啉类化合物的方法。以N-芳基四氢异喹啉类化合物1和丙烯醛2为原料,在手性小分子催化剂存在下合成手性四氢异喹啉类化合物。该方法反应条件温和,环境友好、收率较高、对映选择性好、适合于工业化生产,为合成手性四氢异喹啉类化合物提供了一条简便高效的途径。
本发明所述不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,包括如下步骤:以N-芳基四氢异喹啉类化合物1和丙烯醛2为原料,在手性异辛可宁类似物催化剂、电解质、氮氧自由基和添加剂存在下,有机溶剂中恒流电解反应,得到具有手性四氢异喹啉类化合物3。反应方程式表示如下:
其中:R1选自:氢、卤素、C1-C4烷基、C1-C4烷氧基、苯基、苯氧基或苄氧基;R2选自:氢、卤素、C1-C4烷基或C1-C4烷氧基。
进一步地,在上述技术方案中,所述电解质为六氟硼酸钠。
进一步地,在上述技术方案中,有机溶剂选自N,N-二甲基甲酰胺、二甲基亚砜、二氯甲烷、2,2,2-三氟乙醇、甲醇、四氢呋喃或乙腈。
进一步地,在上述技术方案中,所述氮氧自由基选自2,2,6,6-四甲基哌啶氧化物、4-羟基-2,2,6,6-四甲基哌啶氧化物、4-氨基-2,2,6,6-四甲基哌啶氧化物、4-乙酰氨基-2,2,6,6-四甲基哌啶氧化物或9-氮杂双环[3.3.1]壬烷-N-氧基自由基。
进一步地,在上述技术方案中,所述添加剂选自2,2,2-三氟乙醇、1,1,1,3,3,3-六氟丙-2-醇、甲醇、分子筛、/>分子筛、/>分子筛中的一种或多种。
进一步地,在上述技术方案中,所述恒流指电源输出的电流大小恒定不变,恒流输出电流为1-5mA。
进一步地,在上述技术方案中,所述电解反应温度为0-50℃。
进一步地,在上述技术方案中,所述电极阳极材料选自铂片、网状玻璃态碳、碳毡、石墨碳棒、铂网;电极阴极材料选自镍片、铁片。发明有益效果:
本发明方法原料易得,避免了传统昂贵氧化剂的使用,且得到手性四氢异喹啉类化合物种类繁多,收率较高,对映选择性好,具有潜在放大应用前景。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
实施例1
[a]除非特别说明,反应的步骤如下:1a(41.9mg,0.2mmol)、2(26.8μL,2.0eq)、C1β-ICD(3.1mg,5mol%)、NaPF6(67.2mg,0.1M)、TEMPO(6.3mg,20mol%)、分子筛(120.0mg)、TFE(50.0μL)、CH3CN(4mL),铂片(1.5×1.5×0.02cm3)和铂片(1.0×1.0×0.02cm3)分别作为阳极和阴极,未分割电解槽中,3mA恒定电流,室温条件下通电3小时。[b]分离收率。[c]ee值通过高效液相色谱分离。
反应条件的考察:在非分隔电解槽中,加入2-苯基-1,2,3,4-四氢异喹啉1a(0.2mmol)、丙烯醛2(2.0eq)、β-ICD(5mol%)、NaPF6(0.1M)、TEMPO(20mol%)、分子筛(120.0mg)、TFE(50.0μL)、CH3CN(4mL)。插入电极,连接电源,电解在25℃下3.0mA恒定电流进行,直到底物完全消耗(通过TLC或1H NMR分析监测)。终止反应后,真空浓缩有机相,柱层析得到化合物3a。收率82%,91%ee。HPLC CHIRALCEL OD-H,n-hexane/2-propanol=60/40,flow rate=1.0mL/min,λ=256nm,retention time:6.713min,7.438min;TLC:Rf=0.25(PE:EA=20:1);1H NMR(600MHz,CDCl3):δ9.63(s,1H),7.33-7.28(m,1H),7.26-7.12(m,5H),6.83(d,J=7.8Hz,2H),6.76(t,J=7.2Hz,1H),6.22(s,1H),6.05(s,1H),5.80(s,1H),3.80-3.65(m,1H),3.60-3.40(m,1H),3.10-2.85(m,2H);13C NMR(150M Hz,CDCl3):δ193.4,151.3,148.5,135.7,135.0,134.4,129.2,128.4,128.0,127.3,126.4,118.0,113.9,56.9,43.4,27.9.
实施例2
在非分隔电解槽中,加入2-(4-甲氧基苯基)-1,2,3,4-四氢异喹啉1g(0.2mmol)、丙烯醛2(2.0eq)、β-ICD(5mol%)、NaPF6(0.1M)、TEMPO(20mol%)、分子筛(120.0mg)、TFE(50.0μL)、CH3CN(4mL)。插入电极,连接电源,电解在25℃下3.0mA恒定电流进行,直到底物完全消耗(通过TLC或1H NMR分析监测)。终止反应后,真空浓缩有机相,柱层析得到化合物3g。收率76%,91%ee。HPLC CHIRALCEL OD-H,n-hexane/2-propanol=60/40,flow rate=1.0mL/min,λ=256nm,retention time:5.867min,7.552min;TLC:Rf=0.25(PE:EA=10:1);1H NMR(600MHz,CDCl3):δ9.59(s,1H),7.22-7.05(m,4H),6.83(dd,J=25.8,8.4Hz,4H),6.06(s,2H),5.69(s,1H),3.73(s,3H),3.51(dt,J=100.8,5.4Hz,2H),3.05-2.80(m,2H);13C NMR(150MHz,CDCl3):δ193.4,153.1,151.6,143.4,135.7,135.3,134.7,128.5,128.2,127.1,126.3,117.4,114.7,57.4,55.7,44.2,27.7.
实施例3
在非分隔电解槽中,加入6-溴-2-苯基-1,2,3,4-四氢异喹啉1v(0.2mmol)、丙烯醛2(2.0eq)、β-ICD(5mol%)、NaPF6(0.1M)、TEMPO(20mol%)、分子筛(120.0mg)、TFE(50.0μL)、CH3CN(4mL)。插入电极,连接电源,电解在25℃下3.0mA恒定电流进行,直到底物完全消耗(通过TLC或1H NMR分析监测)。终止反应后,真空浓缩有机相,柱层析得到化合物3v。收率80%,90%ee。HPLC CHIRAL CEL OD-H,n-hexane/2-propanol=60/40,flow rate=1.0mL/min,λ=256nm,retention time:7.000min,8.673min;TLC:Rf=0.23(PE:EA=20:1);1H NMR(600MHz,CDCl3):δ9.60(s,1H),7.35-7.12(m,5H),6.87-6.72(m,3H),6.19(s,1H),6.07(s,1H),5.74(s,1H),3.74-3.64(m,1H),3.52-3.40(m,1H),3.03-2.85(m,2H);13C NMR(150MHz,CDCl3):δ193.3,150.9,148.3,138.1,134.8,134.0,131.0,130.0,129.6,129.3,121.0,118.4,114.1,56.6,43.1,27.7.
实施例4
根据实施例2-3中反应条件,仅仅将反应底物进行改变,得到如下反应结果:
实施例5
在反应管中,加入烯基化反应产物3a(52.7mg,0.2mmol)和2.0mL四氢呋喃,将反应降温至0℃,加入氢化铝锂(15.2mg,0.4mmol)/四氢呋喃(2mL)溶液,室温反应0.5小时。TLC检测反应完全,加水淬灭,干燥,真空浓缩反应液,然后经柱层析(PE/EA=5/1)得到49.3mg无色油状化合物4a(产率93%,87%ee)。[α]D 25=24.53(c=0.318,CHCl3);HPLC CHIRALCELIC-H,n-hexane/2-propanol=60/40,flow rate=1.0mL/min,λ=256nm,retention time:4.387min,9.665min;TLC:Rf=0.27(PE:EA=10:1);1H NMR(600MHz,CDCl3):δ7.26-7.21(m,2H),7.20-7.14(m,3H),7.13-7.09(m,1H),6.94(d,J=8.4Hz,2H),6.79(t,J=7.2Hz,1H),5.33(s,1H),5.25(s,1H),4.83(s,1H),4.17(s,2H),3.70-3.63(m,1H),3.58-3.50(m,1H),2.97-2.80(m,2H),2.36(s,1H);13C NMR(150MHz,CDCl3):δ149.4,149.0,135.9,135.2,129.3,128.6,128.2,127.1,126.0,118.8,115.7,115.1,65.3,62.0,43.8,26.8.
实施例6:
在反应管中,加入烯基化反应产物3a(52.7mg,0.2mmol)和2.0mL四氢呋喃,抽空换氮,将反应降温至-20℃,加入1.6M甲基锂/四氢呋喃溶液(0.19mL,0.3mmol),-20℃反应0.5小时。TLC检测反应完全,加水淬灭,干燥,真空浓缩反应液,经柱层析(PE/EA=5/1)得到39.7mg无色油状化合物4b(产率71%,87%ee,3:1dr)。[α]D 25=5.62(c=0.356,CHCl3);HPLC CHIRALCEL OD-H,n-hexane/2-prop anol=95/5,flow rate=0.6mL/min,λ=256nm,retention time:17.260min,20.333min,27.713min,31.595min;TLC:Rf=0.36(PE:EA=5:1);1H NMR(600MHz,CDCl3):δ7.26-7.19(m,2H),7.19-7.05(m,4H),7.03-6.91(m,2H),6.88-6.77(m,1H),5.42-5.28(m,2H),4.72-4.60(m,1H),4.46-4.38(m,1H),3.75-3.65(m,1H),3.61-3.53(m,1H),3.06(s,1H),2.93-2.83(m,1H),2.76-2.68(m,1H),1.42-1.30(m,3H);13CNMR(150MHz,CDCl3):δ152.9,152.7,149.3,149.2,135.9,135.2,135.0,129.4,129.3,128.9,128.7,128.6,128.6,127.0,127.0,125.9,120.2,119.4,117.5,116.5,115.3,114.0,70.0,69.0,62.4,61.0,43.7,43.5,25.8,25.7,23.0,22.2.
实施例7
在反应管中,加入烯基化反应产物3a(52.7mg,0.2mmol)和2.0mL二氯甲烷搅拌,再将四溴化碳(132.7mg,0.4mmol)、三苯基膦(209.9mg,0.8mmol)缓慢加入到反应管中,室温反应1.0小时。TLC检测反应完全,萃取,干燥,真空浓缩反应液,经柱层析(PE/EA=100/1)得到45.2mg黄色油状化合物4c(产率54%,88%ee)。[α]D 25=-4.93(c=0.214,CHCl3);HPLCCHIRALCEL OJ-H,n-hexane/2-propanol=60/40,flow rate=1.0mL/min,λ=256nm,retention time:5.438min,7.683min;TLC:Rf=0.41(PE:EA=100:1);1H NMR(600MHz,CDCl3):δ7.29-7.11(m,6H),6.90(d,J=7.8Hz,2H),6.83(s,1H),6.79(t,J=7.2Hz,1H),5.50(s,1H),5.26(s,1H),5.17(s,1H),3.69-3.62(m,1H),3.56-3.48(m,1H),2.95(t,J=6.0Hz,2H);13C NMR(150MHz,CDCl3):δ149.4,145.0,136.5,136.2,134.8,129.3,128.5,128.2,127.4,126.2,118.8,118.4,115.0,91.3,63.7,43.8,27.7.
在反应管中,加入产物4c(81.4mg,0.2mmol)和3.0mL二氯甲烷搅拌,再将四丁基氟化铵的四氢呋喃溶液(0.8mL(1.0M),0.8mmol)缓慢加入到反应管中,50℃反应2.0小时。TLC检测反应完全,萃取,干燥,真空浓缩反应液,然后经柱层析(PE/EA=100/1)得到55.5mg黄色油状化合物4d(产率82%,88%ee)。[α]D 25=12.93(c=0.232,CH Cl3);HPLC CHIRALCELOJ-H,n-hexane/2-propanol=60/40,flow rate=1.0mL/min,λ=256nm,retention time:7.982min,9.997min;TLC:Rf=0.41(PE:EA=100:1);1H NMR(600MHz,CDCl3):δ7.31-7.14(m,6H),6.83(d,J=8.4Hz,2H),6.77(t,J=7.2Hz,1H),5.52(s,1H),5.50(s,1H),5.14(s,1H),3.82-3.72(m,1H),3.50-3.40(m,1H),3.08-3.00(m,1H),2.98-2.90(m,1H);13C NMR(150MHz,CDCl3):δ148.9,136.0,134.9,132.3,129.2,128.4,127.8,127.5,126.2,123.0,117.6,113.5,79.4,64.3,52.1,44.0,28.3.
实施例8:
在耐压管中,加入烯基化反应产物3a(52.7mg,0.2mmol)、对甲苯磺酰肼(41.0mg,0.22mmol)和3.0mL无水乙醇,密封,80℃反应4.0小时。TLC检测反应完全,萃取,干燥,真空浓缩反应液,然后经柱层析(DCM/MeOH=100/1)得到65.6mg黄色固体化合物4e(产率76%,90%ee)。m.p.187.5–188.9℃,[α]D 25=9.85(c=0.315,CHCl3);HPLC CHIRALCEL OD-H,n-hexane/2-propanol=60/40,flow rate=1.0mL/min,λ=256nm,retention time:5.848min,12.915min;TLC:Rf=0.37(PE:EA=3:1);1H NMR(600MHz,DMSO-d6):δ11.53(s,1H),7.79(d,J=7.8Hz,2H),7.67(s,1H),7.40(d,J=7.8Hz,2H),7.22(d,J=7.8Hz,1H),7.19-7.12(m,2H),7.09(t,J=7.8Hz,1H),6.95(t,J=7.2Hz,1H),6.67(t,J=7.2Hz,1H),6.59(d,J=7.8Hz,2H),5.65(s,1H),5.48(s,1H),5.39(s,1H),3.80-3.70(m,1H),3.40(s,1H),3.36-3.29(m,1H),3.06-2.90(m,2H),2.42(m,3H);13C NMR(150MHz,D MSO-d6):δ148.0,147.6,146.0,143.4,136.1,135.6,135.4,129.7,128.8,127.8,127.7,127.3,126.8,125.8,122.0,116.6,112.5,56.9,43.3,27.5,21.1
以上实施例描述了本发明的基本原理、主要特征及优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明原理的范围下,本发明还会有各种变化和改进,这些变化和改进均落入本发明保护的范围内。
Claims (8)
1.不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,其特征在于,包括如下步骤:以N-芳基四氢异喹啉类化合物1和丙烯醛2为原料,在手性异辛可宁类似物催化剂、电解质、氮氧自由基和添加剂存在下,有机溶剂中恒流电解反应,得到具有手性四氢异喹啉类化合物3;反应方程式表示如下:
R1选自:氢、卤素、C1-C4烷基、C1-C4烷氧基、苯基、苯氧基或苄氧基;R2选自:氢、卤素、C1-C4烷基或C1-C4烷氧基。
2.根据权利要求1所述不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,其特征在于:电解质为六氟硼酸钠。
3.根据权利要求1所述不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,其特征在于:有机溶剂选自N,N-二甲基甲酰胺、二甲基亚砜、二氯甲烷、三氟乙醇、甲醇、四氢呋喃或乙腈。
4.根据权利要求1所述不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,其特征在于:所述氮氧自由基选自2,2,6,6-四甲基哌啶氧化物、4-羟基-2,2,6,6-四甲基哌啶氧化物、4-氨基-2,2,6,6-四甲基哌啶氧化物、4-乙酰氨基-2,2,6,6-四甲基哌啶氧化物或9-氮杂双环[3.3.1]壬烷-N-氧基自由基。
5.根据权利要求1所述不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,其特征在于:所述添加剂选自2,2,2-三氟乙醇、1,1,1,3,3,3-六氟丙-2-醇、甲醇、分子筛、/>分子筛、/>分子筛中的一种或多种。
6.根据权利要求1所述不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,其特征在于:所述恒电流指电源输出的电流大小恒定不变,恒流输出电流为1-5mA。
7.根据权利要求1所述不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,其特征在于:所述电解反应温度为0-50℃。
8.根据权利要求1所述不对称脱氢偶联合成手性四氢异喹啉类化合物的方法,其特征在于:所述电极阳极材料选自铂片、网状玻璃态碳、碳毡、石墨碳棒、铂网;电极阴极材料选自镍片、铁片。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311057957.5A CN117026253A (zh) | 2023-08-22 | 2023-08-22 | 不对称脱氢偶联合成手性四氢异喹啉类化合物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311057957.5A CN117026253A (zh) | 2023-08-22 | 2023-08-22 | 不对称脱氢偶联合成手性四氢异喹啉类化合物的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117026253A true CN117026253A (zh) | 2023-11-10 |
Family
ID=88633413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311057957.5A Pending CN117026253A (zh) | 2023-08-22 | 2023-08-22 | 不对称脱氢偶联合成手性四氢异喹啉类化合物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117026253A (zh) |
-
2023
- 2023-08-22 CN CN202311057957.5A patent/CN117026253A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111286748B (zh) | 一种电化学合成咔唑类化合物的方法 | |
WO2020147861A1 (zh) | 一种β-三氟甲基酰胺类化合物的电化学制备方法 | |
Du et al. | Regio-and stereoselective electrochemical synthesis of sulfonylated enethers from alkynes and sulfonyl hydrazides | |
AU2016311135A1 (en) | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and recovery of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide by electrochemical methods | |
CN109402659B (zh) | 一种α-硫代烯胺类化合物的绿色合成方法 | |
CN111910209A (zh) | 一种3-芳硒基喹啉酮化合物的电化学合成方法 | |
CN114540845A (zh) | 一种2,2`-双琥珀酰亚胺衍生物的电化学合成方法 | |
CN112501642B (zh) | 一种3-芳硒基-4-胺基香豆素化合物的电化学合成方法 | |
CN110616439A (zh) | 电化学氧化合成4-磺酸取代异喹啉酮衍生物的方法 | |
CN113200914A (zh) | 一种炔基化四氢异喹啉类化合物及其制备方法与应用 | |
CN117026253A (zh) | 不对称脱氢偶联合成手性四氢异喹啉类化合物的方法 | |
JP3946260B2 (ja) | フタリドの製法 | |
CN113930793B (zh) | 一种利用电化学微通道反应装置制备3-甲基-5-溴甲基吡啶溴酸盐的方法 | |
CN115233243A (zh) | 一种电催化下2,4,5-三取代噁唑衍生物的制备方法 | |
CN114438523A (zh) | 一种绿色高效的苯并噻吩类化合物电化学合成方法 | |
CN109761963B (zh) | 一种9-氮杂环取代的氧杂蒽类化合物的制备方法 | |
CN112940227A (zh) | 一种侧链含有tempo的聚咔唑及其制备方法和应用 | |
JPS6342713B2 (zh) | ||
JPH01312094A (ja) | ヒドロキシカルボン酸エステルの製法 | |
CN112359375B (zh) | 一种电化学合成3-烷硒基-4-氨基香豆素化合物的方法 | |
JPH0219195B2 (zh) | ||
JPS6240389A (ja) | カルバミン酸エステルの製法 | |
CN111945181B (zh) | 一种3-烷硒基喹啉酮化合物的电化学合成方法 | |
JPS6342712B2 (zh) | ||
JP4613066B2 (ja) | 有機塩及び電気化学反応における試薬としてのその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |